Histone deacetylase 10, a potential epigenetic target for therapy

Fajuan Cheng¹,², Bin Zheng³,⁴,⁵†, Jianwei Wang⁶, Guiting Zhao⁴,⁵, Zhongshun Yao⁴,⁵,*
Zhihong Niu³,⁴,⁵*, Wei He⁴,⁵*

¹ Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University,
Jinan, Shandong, China.
² Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First
Medical University, Jinan, Shandong, China.
³ Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China;
⁴ Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical
University, Jinan, Shandong, P.R. China;
⁵ Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University,
Jinan, Shandong, P.R. China;
⁶ Department of Urology, Shandong Provincial ENT Hospital Affiliated to Shandong University,
Jinan, Shandong, P.R. China;
† These authors contributed to this work equally.

*Corresponding to:
Zhihong Niu, Wei He

1. Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China;
2. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical
University, Jinan 250021, Shandong, China;
3. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University,
Jinan 250021, Shandong, China;
Tel: +86-053168776310; Fax: +86-053168776310;
E-mail: nzh1789@163.com (Z,H,N). Hewei@bjmu.edu.cn (W,H).

Number of words: 4705
Abstract

Histone deacetylase (HDAC) 10, a class II family, has been implicated in various tumors and non-tumor diseases, which makes the discovery of biological functions and novel inhibitors a fundamental endeavor. In cancers, HDAC10 plays crucial roles in regulating various cellular processes through its epigenetic functions or targeting some decisive molecular or signaling pathways. It also has potential clinical utility for targeting tumors and non-tumor diseases, such as renal cell carcinoma, prostate cancer, immunoglobulin A nephropathy, intracerebral hemorrhage, human immunodeficiency virus (HIV) infection and schizophrenia. To date, relatively few studies have investigated HDAC10-specific inhibitors. Therefore, it is important to study the biological functions of HDAC10 for the future development of specific HDAC10 inhibitors. In this review, we analyzed the biological functions, mechanisms, and inhibitors of HDAC10, which makes HDAC10 an appealing therapeutic target.

Key words: cancer, disease, epigenetics, histone deacetylases, HDAC10
1. Introduction

Nuclear DNA in eukaryotic cells always combines with histones before packaging into the chromatin. However, a fundamental question is how the chromatin is regulated when and where it is necessary. The existed evidence presented that ATP-dependent chromatin remodeling as well as covalent chromatin modification may contribute to this regulation (1). Covalent chromatin modification includes acetylation, phosphorylation, methylation, ubiquitination and ADP-ribosylation (2, 3). Acetylation, as the first discovered modification, is the most studied and best characterized among all modifications. There is compelling evidence that acetylation of lysine residues at amino acid termini greatly affects transcriptional regulations (2).

Histone deacetylases (HDACs) serve as a ‘eraser’, which remove acetate from acetylated histone as well as other non-histone proteins (4, 5). Generally, HDACs are also known as lysine acetyltransferases as well as lysine deacetylases (6). Additionally, HDACs exert effects on posttranslational modifications, such as ubiquitination, and methylation, and can influence gene transcription by increasing the interaction between DNA and histone (7-9). In eukaryotic cells, HDACs may come from prokaryotic enzymes, similar to acetylpolyamine amidohydrolases (7, 10). Currently, HDACs are divided into four classes (11). In 2002, Fischer DD et al (12), Tong JJ et al (5), Kao HY (13) and Guardiola AR, Yao TP (14) reported a novel enzyme that shares functional characterizations with other class II members, and named it HDAC10.

In this review, we focus our attention on the progress of studies on the role of HDAC10 in various tumors and non-tumor diseases. Particular emphasis is given to its functions and mechanisms.

2. Structures and catalytic mechanisms of different HDACs

2.1 Structures of class II HDACs

Class II HDACs are subclassified as IIa and IIb. Class IIa HDACs (HDAC4, 5, 7, 9) are defined by a functionally essential N-terminal domain, which can regulate nuclear-cytoplasmic shuttling as well as specific DNA-binding. The cellular trafficking of class IIa HDACs is determined by intrinsic nuclear import or export signals as well as specific binding sites for 14-3-3 proteins (15). Through binding with the 14-3-3 proteins, Class IIa HDACs can stimulate cytoplasmatic retention and nuclear export in a phosphorylation dependent manner. These
processes in turn affect the activity of transcription factors, such as myocyte enhancing factor-2 (16, 17).

Class IIb HDACs include HDAC6 and HDAC10. HDAC6 contains two tandem deacetylase domains and a C-terminal zinc finger (18). HDAC10 is structurally related to HDAC6. The HDAC10 gene localizes to chromosome 22 (14). Consisting of 20 exons, HDAC10 contains two spliced transcripts (5, 12) and also contains an N-terminal catalytic domain as well as a C-terminal leucine-rich domain. Specifically, the N-terminal catalytic domain of HDAC10 is similar to the deacetylase domain of other known class II HDACs, but the C-terminal catalytic domain does not contain residues that are necessary for enzymatic functions. The existence of both domains may confer resistance to trapoxin B and sodium butyrate (5, 14). HDAC10 is member of the arginase/deacetylase superfamily and is expressed differentially in the cytoplasm and nucleus (10, 12). It may also repress transcription except for the deacetylation activity in the nucleus (14). Moreover, HDAC10 expressed in most human tissues, including the kidney, pancreas, liver, spleen, heart, testis, brain, and placenta (5). Emerging evidence has established that HDAC10 is responsible for the regulation of polyamine. Using X-ray crystallography, researchers have observed that HDAC10 has a unique conserved glutamate gatekeeper that may promote N8-acetylsperrmidine hydrolysis, serving as a polyamine deacetylase (PDAC) (6, 19).

Noticeably, class II HDACs show 23–81% amino acid similarity with conserved deacetylase domains. Moreover, they all have cytoplasmic localization, which implies that class II HDACs play significant role in cytoplasmic functions (13, 20, 21).

### 2.2 Catalytic mechanisms of HDACs

Class I, II, and IV HDACs require zinc ion to exert enzyme activity. The X-ray crystallography has determined catalytic domain structures of Class I, II and IV HDACs, which contains open α/β-family of folds and stranded parallel β-sheets (22). These structures make contributions to the binding of HDACs active sites and HDAC inhibitors. A model of action proposed by Wu et al. (23) suggested that H143, a histidine residue, could function as a base to accept protons from zinc-bound molecules in a rate-determining step. Then the accepted proton will be shuttled to the amide nitrogen atom to facilitate the cleavage of amide bond (24).
The class III HDACs has a common model of action that requires cofactor NAD⁺(25). A structural study found that the catalytic domain of class III HDACs locates in a cleft, which could constitute a protein-tunnel where the substrate could combine with NAD⁺. Mechanically, based on the catalytic structure of class III HDACs, cleavable nicotinamide from NAD⁺ and ADP-ribose could transfer to acetylated lysine(26).

3. Biological characterization and mechanism of HDAC10 in tumors

In 2000 and 2011, Hanahan and Weinberg proposed six and additional four hallmarks of tumors, respectively(27, 28). These conceptions promoted the understanding of the diversity of tumors. Here, we focus mostly on HDACs that affect the biology of tumors, tumorigenesis, and summarize the mechanistic underpinnings concerning cell proliferation, cell apoptosis, cell invasion, migration, metastasis, angiogenesis and other tumor-related biological functions (Figure. 1, Table. 1).

3.1 HDAC10 and cell proliferation

HDAC10 plays an essential role in the regulation of cancer cell growth. It has been demonstrated that it can prompt cell proliferation in non-small cell lung cancer (NSCLC)(29). In contrast, HDAC10 suppresses cancer cell growth in other malignant tumors, including lung adenocarcinoma(30) and renal cell carcinoma (RCC)(31). Akt is a key molecule in the PI3K-AKT pathway, and is involved in cell proliferation, survival, and other key functions(32). Analogously, HDAC10 overexpression significantly facilitates NSCLC cell growth by regulating the Ser473 phosphorylation of AKT(29). In lung adenocarcinoma, deletion of HDAC10 accelerates the progression of KRAS-driven cancer both in vivo and in vitro. Specifically, by activating the transforming growth-factor β (TGF-β) pathway, deletion of HDAC10 promotes the expression of SOX9, which subsequently upregulates the expression of SLUG, as well as CD44. These processes contributes to the growth of lung cancer spheres via sex determining region Y box protein 9 (SOX9)-mediated stem-like properties, suggesting that HDAC10-TGF-β-SOX9-SLUG/CD44 axis plays an essential role in lung adenocarcinoma (30).

AMP-activated protein kinase (AMPK) regulates biological functions in tumors that are mediated by liver kinase B1 (LKB1), such as cell survival and transcription, via the mTOR
pathway(33). Induced by LKB1–AMPK signaling, phosphorylated HDAC10 is transported from the nucleus to the cytoplasm and further enhances the expression of glucose-6-
phosphate dehydrogenase (G6PD). This decreases the level of reactive oxygen species (ROS)
and promotes lung cancer cell proliferation(34). The cases described above suggest that the
LKB1–AMPK-HDAC10-G6PD-ROS pathway might be important to tumor cell proliferation.
However, in RCC cells, suppressed expression of HDAC10 significantly promotes the
phosphorylation of β-catenin and thus plays a part in anti-proliferation(31)(Figure. 1a).

Perturbed cell cycle is also a growth-regulation way in cancer cell(35). Previous studies have shown that by inhibiting histone H3 deacetylation around the let-7f-2/miR-98 promoter,
HDAC10 suppresses HMG2 expression which target to cyclin A2 promoter, and further
inhibits the transcription of cyclin A2(30, 36). The signaling pathways: HDAC10-let-7f-2/miR-
98-HMG2-cyclin A2 arrests the G2/M transition and finally inhibits lung cancer cell proliferation. Evidence suggests that both cell cycle inhibitors (such as P21 and P27) and
promoters (such as cyclins E1 and D1) play a vital role in cancer progression(37-39). HDAC10 plays an oncogenic role by inhibiting the expression of P27, P21 and enhancing that of cyclins D1 and E1 (29) (Figure. 1a).

3.2 HDAC10 and cell apoptosis

Cancer cells will not die in a scenario that too little apoptosis happens(40). Numbers of
proteins and signaling are involved in cell apoptosis. It has been established that overexpressed
antiapoptotic proteins (such as those in the Bcl-2 family) as well as downregulated proteins (such as Bid, BIK and BAK) may disrupt the balance between apoptosis and anti-apoptosis(41, 42). By targeting AKT, HDAC10 affects the expression of B-cell lymphoma-2 (BCL2) as well as BCL2 antagonist/killer (BAK), which induces apoptosis in lung carcinoma(29). In colorectal cancer, inhibited HDAC10 expression promotes cell apoptosis by depleting transcription factor 7 like 2 (TCF7L2), which attenuates the Wnt pathway (43). ROS, generated from mitochondrial damage or oxidative stressors, may promote caspases and induce apoptosis(44, 45). Lee et al found that a low level of HDAC10 in gastric cancer may activate proapoptotic molecules including caspase-3, caspase-9, and Bid through the thioredoxin interacting protein (TXNIP)-induced ROS signaling pathway(46) (Figure. 1b). Although previous studies have determined
limited mechanisms in lung, colorectal and gastric tumors, including the HDAC10-AKT-BCL2-BAK pathway, the HDAC10-TCF7L2-Wnt pathway, and the HDAC10-TXNIP-ROS-caspase-3/caspase-9/Bid pathway, it is not yet clear whether these mechanisms exist in other tumors(29, 43, 46). Therefore, advances in research on the mechanisms of HDAC10 will be key to unraveling its potential importance in tumors.

3.3 HDAC10 and cell metastasis

Tumor cell metastasis is a multistep process including cell adhesion, invasion, migration, and dissemination at distant organs(47, 48). Invasion- and migration-related molecules, such as matrix metalloproteinases (MMPs), and S100A10 are dysregulated in various cancer cell lines(49-51). Zhao et al(52) reported that HDAC10 shows low expression levels in pulmonary giant cell carcinoma cells and is subject to regulation by connexin 43 (Cx43). As Cx43 is overexpressed, the expression of follistatin-like 1 (FSTL1) is elevated, via the enhanced binding between HDAC10-mediated acetylation of H3 and H4 and the promoter of FSTL1. The Cx43-HDAC10-FSTL1 axis not only contributes to the low expression levels of S100A10, MMP-2, and laminin subunit alpha 4 (LAMA4), but also enhances the expression of MTSS I-BAR domain containing 1 (MTSS1), which plays a pivotal role in the suppression of both invasion and metastasis(52). In metastatic cervical squamous cancer cells, HDAC10 serves a tumor suppressor role through the regulation of MMPs. Mechanistically, due to the combination of HDAC10 and the promoters of MMP-2 (especially the AP1-binding site) and MMP-9 (especially the NF-κB- and sp1-binding sites) the decreased level of histone acetylation impedes the binding function of polymerase II, weakens the expression levels of MMP-2 and MMP-9 and restrains cancer cell invasion and migration(53). HDAC10 also deacetylates acetyl-H3K9/14 and acetyl-C/EBPα, preventing their recruitment to the promoter of miR-223 in sulfatide-treated hepatocellular cancer (HCC) cells. The low expression of miR-223 further facilitates the expression of integrin αV subunit and then attenuates HCC cell migration as well as metastasis(54). The β-catenin pathway is altered in various tumors and also plays important roles in carcinogenesis(55, 56). In renal cell carcinoma (RCC), overexpressed HDAC10 restrains RCC cell invasion by inhibiting phosphorylated nuclear β-catenin expression(31) (Figure. 1c). Although these studies are interesting, they were mainly based on overexpression
experiments. Therefore, the mechanism of HDAC10 in tumor metastasis must be characterized in more detail.

3.4 HDAC10 and angiogenesis

Angiogenesis is an indispensable process in the early stage of tumor growth(57). Angiogenesis involves several pro-angiogenic proteins, including vascular endothelial growth factor (VEGF), TGF-β, extracellular regulated protein kinases (ERK) and others(58-60). Duan et al(61) reported that overexpressed HDAC10 deacetylates H3 and H4 in promoter of phosphatase and tensin homolog 22 (PTEN22) and consequently inhibits polymerase II from binding to PTEN22 promoter. The suppressed expression of PTEN22 subsequently increases ERK1/2 activation and ultimately facilitates the formation of tubes in vivo and in vitro. Because of this, it was speculated that the HDAC10-PTEN22-ERK1/2 signaling pathway may contribute to tumor angiogenesis. HDAC10 also regulates angiogenesis via depletion of VEGFR in gastric- and colon cancer cell. Mechanistically, HDAC10 obstructs heat shock protein (Hsp) 90 bound to vascular endothelial growth factor receptor 1 (VEGFR1)/ VEGFR2, but promotes the combination between Hsp70 and VEGFR1/VEGFR2(62). This imbalanced binding leads to proteasomal-dependent degradation of VEGFRs, which may regulate angiogenesis (Figure. 1d).

3.5 HDAC10 and drug resistance

Drug resistance is a common phenomenon during chemotherapy. It not only limits the therapeutic effect but can even lead to treatment failure(63). The altered drug metabolism, mutated drug targets and elevated drug efflux rate contribute to drug resistance(64, 65). Downregulation of HDAC10 may restore the sensitivity of doxorubicin in neuroblastoma. Ridinger et al(66) reported that suppressing HDAC10 expression promotes intracellular accumulation of doxorubicin by inhibiting lysosomal exocytosis, which results in cell death with enhanced double-strand breaks (DSBs) as well as DNA damage. Additionally, autophagy, activated via therapeutic stress, participates in drug resistance and multidrug resistance (MDR)(67). Consistent with this point, Oehme et al(68, 69)found that HDAC10 deletion acetylated Hsp70/heat shock cognate 70 (Hsc70), and impairs the autophagic flux by thwarting the blend between autophagosomes and lysosomes, which allows drug-resistant neuroblastoma
cell to recover sensitivity to doxorubicin. A study that combined bioinformatic analyses and cell experiments found that low HDAC10 expression both intensifies the cytotoxicity of ovarian cancer cells to cisplatin and constrains DNA repair(70).

Many cytotoxic events can break DNA double strands and result in cell death(71). Encountering DNA damage, various proteins, such as human single-stranded DNA binding protein 1 (hSSB1), will repair the flawed sites(72). Wu et al.(73) found that p300 acetylates hSSB1 lysine 94 when it localizes to impaired sites, and recovers DNA stability. However, upregulated HDAC10 reverses this process and makes tumor cells more responsive to chemotherapy. Castration-resistant prostate cancer (CRPC), arising from resistance to androgen deprivation therapy (ADT), is a tricky problem(74). Previous studies have reported that bromodomain and extra-terminal protein inhibitor (BETi) can deteriorate the androgen receptor signaling pathway. Moreover, in prostate cancer cells, elevated expression of bromodomain-containing protein 4 (BRD4, a member of BET family), induced by BETi, confers resistance to these inhibitors(75, 76). Jin et al(77) found that low expressed nuclear receptor co-repressor 2 (NCOR2)-HDAC10 complex is negatively associated with deubiquitinase ubiquitin specific peptidase 17 like family member 2 (DUB3), which may interact with BRD4 and further inhibit sensitivity to BETi in prostate cancer cells and in vitro. Although the roles of HDAC10 in drug resistance have not been explored completely, experiments suggest that the NCOR2-HDAC10-DUB3-BRD4 signaling pathway might be useful as a regulator of drug resistance in tumors(77).

Androgen receptor (AR) is a significant target in treating CRPC, and silencing HDAC10 also reduces the transcriptional activity of androgen receptor (AR)-V7 and full length AR (flAR) in prostate cells(78), which implies that HDAC10 has potential therapeutic value.

3.6 Other biological functions
Cancer stem cells (CSC) are cells hidden in tumors that are capable of promoting tumor growth, progression, and resistance treatments(79, 80). Many molecules, such as SOX9, SLUG, and CD44, may help determine stem cell state(81, 82). In lung adenocarcinoma, SOX9, SLUG and CD44 are activated by the downregulation of HDAC10 and stimulation of TGF-β, which mediates CSC-related cancer progression(30). HDAC10 impacts immune and inflammation function as well. HDAC10-deleted Foxp3+ Treg cells have immunosuppressive functions and
may play roles in alleviating immune-related colitis and prolonging cardiac allograft survival in MHC-mismatched mice (83). HDAC10 deletion also recruits massive macrophages (especially M2 macrophages) into the lung cancer microenvironment. Considering that M2 macrophages may secrete anti-inflammatory molecules and promote tumor activity, HDAC10 may accelerate tumor progression by increasing tumor inflammation (30, 84). An additional effect of deletion of HDAC10 is chaperone-mediated autophagy (CMA), a form of autophagy that occurs via selective cytosolic protein transfer (85). In knockout HDAC10 cervical cancer cell, Obayashi et al (86) identified that increased expression levels of lysosomal associated protein 2 A (LAMP2A) and increased accumulation of LAMP2A-positive lysosomes near the nucleus raised, which may be a sign of activated CMA (87, 88). This characteristic may be effective for cancer treatment.

The mismatch repair system (MMR) is important in correcting flaws happened in the stage of DNA replication (89). It has been shown that mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), and MSH6 commonly participated in MMR (90). HDAC10 can trigger MSH2 activity initiated by MSH2 deacetylation at lysine 73 in HeLa cells, following improved MMR activation (91). A study that compared colon cancer cells and adjacent cells also revealed that low HDAC expression level in normal cells were negatively correlated with MSH2, MLH1 and MSH6 (92). This may account for the different prognoses between normal and tumor cells.

HDAC10 can perform regulatory roles through other epigenetic modifications, i.e., transcription regulation, methylation and promoter polymorphism (93-95). In adrenocortical cancer cells and adenoma cells, HDAC10 is significantly methylated and its expression level dramatically decreases with hypermethylation (94). Uzdensky et al (95) observed downregulated HDAC10 during transcription deregulation of melanoma progression. HDAC10 also participates in influencing the occurrence and onset age of HBV infection in HCC patients due to the promoter polymorphism, notably HDAC10-589C>T. The “T” allele in HDAC10-589C>T enhances transcription activity, and might spur HCC progression by increasing HDAC10 expression (93). Other study identified that frame-shift deletions, one type of repeated alterations, occurred in HDAC10 among anaplastic thyroid cancer specimen (96). According to Lourdusamy et al. (97), a large number of genes, including BRD1, HIRA, and HDAC10 are expressed at low levels in spinal ependymoma. However, the detailed mechanisms underlying
the activity of HDAC10 in spinal ependymoma still need to be elucidated. These studies may manifest an alternate form of tumor regulation (Figure. 2a). It is worth noting that the specific mechanisms of the involvement of HDAC10 in other functions also remain unresolved, and further studies are need. Nonetheless, the studies reviewed herein demonstrate the promise of HDAC10 as a molecular target for cancer.

4. Prognostic roles of HDAC10

The potential prognostic roles of HDAC10 have been explored. Up-regulated HDAC10 is associated with favorable overall survival (OS) in colon cancer, gastric cancer, RCC, and NSCLC patients(31, 92, 98, 99). However, it should be noted that Liu et al.(100) studied the OS data of 180 NSCLC patients and found that up-regulated HDAC10 predicted poor OS. Moreover, HDAC10 is also an independent predictor of treatment free survival (TFS) as well. HDAC10 level is associated with poor TFS in chronic lymphocytic leukemia (CLL)(101). In this disease, high expression levels of HDAC are indirectly associated with a poor prognosis (102-104). PD-L1 is expressed in various cancers and its clinical therapeutic value has been validated(105). Due to enhanced PD-L1 expression in NSCLC patients with high HDAC10 expression, HDAC10 could function as a biomarker for the evaluation of PD-L1 treatment(100).

The elevated radio-sensitization caused by inhibiting HDAC10 involves downregulation of Rad51a, a component of DNA repair pathways(106). In addition, positive HDAC10 expression is correlated with adverse clinical features, such as larger tumor size, poor tumor stage, and more lymph node metastasis (99) (Figure. 2b).

5. HDAC10 in other non-tumor diseases and its pathophysiological functions

5.1 Respiratory system diseases

An important role of HDAC10 has been found in asthma-induced eosinophilic airway inflammation. Zhang et al(107) demonstrated that glucocorticoid (GC) and anacardic acid (AA) have the ability to alleviate IL-4, IL-5, and IL-13 and ameliorate airway inflammation in vivo, which depends on the low histone acetylation induced by elevated HDAC10 in memory T cell. A study that examined titanium dioxide (TiO₂), a latent occupational carcinogen(108) in lung cells, reported that TiO₂ particles provoked ROS (especially superoxide) and HDAC10...
expression after lung cell are treated at 100 μg/cm² and 160 μg/cm² for 24 h, respectively(109).

This implies that heritable epigenetic changes may serve as a reply to TiO2 particle exposure. Moreover, HDAC10 is also a potential pathogenic gene in emphysema(110).

5.2 Urinary system diseases

HDAC10 is also a latent biomarker in immunoglobulin A nephropathy (IgAN) and renal fibrosis as well(111, 112). HDAC10 protein levels are significantly higher in fibrotic kidneys. However, piceatannol treatment does not diminish HDAC10 expression but the results hint that HDAC10 may regulate renal fibrosis via other signaling pathways(111). To determine a biomarker for IgAN, Guo et al(112) utilized samples from the Gene Expression Omnibus (GEO) database and found that HDAC10 existed in monocytes of IgAN samples, which enriches in both alcoholism and chromatin modifying enzymes via construction of functional interaction (FI) network.

5.3 Nervous system diseases

HDAC10 is associated with many nervous system diseases. Kebir et al(113) indicated that one single nucleotide polymorphism (SNP) (rs7634112) located in HDAC10 is significantly associated with schizophrenia. They devised a model that incorporates HDAC10, HDAC3, and HDAC9 to divide schizophrenia patients with high accuracy. A Korea study confirmed these results and selected a new SNP (rs1555048) for the Korean population(114).

Wang et al(115) reported that decreased HDAC10 expression may aggravate post intracerebral hemorrhage inflammation by elevating downstream PTPN22 and activating NLRP3 inflammasomes in rats. HDAC10 can modulate drug addiction as well. González et al(116) reported that single dose methamphetamine (METH) enhances HDAC10 expression in the medial prefrontal cortex of rat and that such up-regulation influences H4ac enrichment, which may account for the modified cognitive functions observed after using psychostimulants. The translocation of Olig1 protein involves brain development as well as multiple sclerosis(117, 118). In oligodendrocytes, HDAC10 represses Olig1 lysine 150 acetylation, which leads to Olig1 protein being retained in cytoplasm(119). In mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS), HDAC10 mRNA is significantly up-regulated. Meanwhile,
increased HDAC10 expression has also been found in cytoplasm instead of the nucleus (120). This sub-cellular distribution hints at potential role of HDAC10 in regulating MTLE-HS pathophysiology.

5.4 Hormone regulation

Many studies have opened new doors into the potential functions of HDAC10 in hormone regulation. Xu et al.(121) found that the alteration of decreased luteinizing hormone (LH) surge stimulated by estradiol (E2) in middle age female rats may mediated by HDAC10. Specifically, in the anterior hypothalamus, the attenuated HDAC10 expression and enhanced H3 acetylation induced by E2 were not observed in middle age female rats. A study from China illustrated the important role of HDAC10 in melanogenesis (122). HDAC10 restores melanogenesis by deacetylating paired box protein 3 (Pax3) and KRAB-associated protein 1 (KAP1), which relieves the repressed promoters of microphthalmia-associated transcription factor (MITF) as well as tyrosinase-related protein 1 (TRP-1) and TRP-2 in melanoma cells (122). These processes ultimately prove melanogenesis mainly achieved through HDAC10/Pax3/KAP1 pathway.

5.5 Lipid metabolism

The role of HDAC10 in regulating lipid metabolism has also been investigated. Qian et al. (123) found that HDAC10 expression decreases in obese humans and other animals (including mice and monkeys). In one study, the level of HDAC10 was markedly reduced in the medial hypothalamus of fasting mice, but researchers did not investigate its impact on AcH3 and AcH4 expression (124). A study of benzyl butyl phthalate (BBP) found that it reduces HDACs (including HDAC10) and further contributes to acetylation of H3K9, which drives adipogenesis in mesenchymal stem cells (MSCs) (125).

5.6 HIV infection

The pathogenetic mechanisms of human immunodeficiency virus (HIV) are still being explored, which is crucial to develop blockbuster drugs (126). Recent research suggests that HDAC10 takes part in HIV infectivity and thus can be used for its treatment (127-129). Ran et
al. identified that a virus-associated envelop glycoprotein (vEnv), one type of defective viral particle, mediates histone deacetylation via downregulation of HDAC10 in Jurkat T-cell, which ultimately elevates the infectivity of the virus and leads to HIV infection(127). In CD4+ T-cells, downregulating HDAC10 expression promotes HIV-1 replication by increasing its interaction with DNA. Meanwhile, HDAC10 also combines with HIV-1 integrase (IN), lessening its reciprocal action with cellular protein lens epithelium-derived growth factor (LEDGF/p75), and ultimately deteriorating HIV-1 integration, which makes HDAC10 an inhibitor of HIV-1 replication(128). Currently, antiretroviral drugs can prolong the life expectancy of HIV patients since it was introduced(130). Rodriguez et al reported that both raltegravir alone and in combination with morphine facilitate the level of HDAC10(129). However, further investigation is necessary to illustrate the underlying therapeutic mechanism.

5.7 Other diseases

HDAC10 orchestrates various biological functions. Pinto et al(131) found that HDAC10 may mediate nutrition-associated growth. After restricting food in vivo or starving serum in vitro, HDAC10 expression apparently increased which is induced by inhibiting mTOR, and elevated levels of HDAC10 activated autophagy via Hsp70 deacetylation, thereby repressing cell viability(131). HDAC10 is also affects inflammation in the temporomandibular joint. Downregulated HDAC10 suppresses the IL-1β/NF-κB pathway and its related inflammatory response in vitro(132). In addition, in embryonic as well as induced pluripotent stem cells, HDAC10 enhances the level of chromatin remodelers(133). In retinal ganglion cells, excitotoxicity alters HDAC10 localization to the cytoplasm(134). In patients with vasospastic angina, apparently DNA gain was observed in HDAC10(135). However, it remains to be explored the detailed HDAC10-related mechanism or therapeutic value (Table. 2).

6. HDAC10 inhibitors

After constructing the homology model structure of HDAC10, Uba AI et al further validated its reliability(136, 137). A group, focused on the tunnel behavior of HDAC10, suggested that the amino acids in tunnel-like sites of HDAC10 are subtly different from other HDACs (such as HDAC8, and HDAC11) and identified a non-conserved amino acid in the wall
of these sites(138). Researchers have also found that HDAC10 contains Zn$^{2+}$-binding groups and has additional interactions with inhibitors when accommodating with them(139). Moreover, the X-ray crystal structure of zebrafish HDAC10 indicates that the gatekeeper E274 and humanized PEACE motif helix are the structural bases of high-selective HDAC10 inhibitors(140). These results conduct a useful model and support the development of HDAC inhibitors (HDACIs) with reliable information.

6.1 Selective and non-selective HDAC10 inhibitors

Nowadays, many HDACIs exhibit potent broad spectrum repression ability to HDACs (including HDAC10), examples in broad spectrum HDACIs include suberoylanilide hydroxamic acid(141), CRA-024781(142), CRA-026440(143), AR42(144), trichostatin A (TSA)(145), valproic acid (VPA)(146) and so on. Both CRA-024781 and CRA-026440 are novel hydroxamic acid-based HDACIs that show potency against a series of HDACs, including HDAC1,2,3,6,8 and 10. CRA-024781 and CRA-026440 have in vitro efficacy in suppressing tumor cell proliferation as well as angiogenesis, inducing apoptosis and inhibiting tumor growth in vivo(142, 143). Another group reported pan-HDACIs AR42 and sodium valproate, which also have great selectivity over HDAC1,3,8 and 10 and obvious anti-tumor properties were observed in vivo and in vitro following pre-treatment with these HDACIs. Notably, AR42 and sodium valproate diminish PD-L1 and PD-L2 expression, and consequently elevate the efficacy of pazopanib, which increases multiple immune cells, for instance M1 macrophage, neutrophils, NK cells, and T cells(144). In addition, TSA can inhibit HDAC10 and 6, and the selectivity over HDAC10 arises from its N-terminal domain(147). In colorectal cancer cells, TSA induces the inhibition of HDAC10 as well as HDAC6, and subsequently attenuates the Wnt pathway by the deletion of the Wnt signaling pathway-associated factor TCF7L2 in a proteasome-dependent way, which suppresses cell proliferation in vitro(43). Bufexamac, an anti-inflammatory drug screened out via a new protocol, is also selective for HDAC10 and HDAC6 and its cellular potency may rely on interferon-α secreted by mononuclear cells(148) (Figure. 3).

However, due to some severe adverse effects of multitarget HDACIs(149), Géraldy et al.(150) investigated HDAC10-specific inhibitors and found that tubastatin A tightly binded to
HDAC10 in HeLa cells with its basic amine in the cap group. Based on an HDAC10 homology model, they revealed that a hydrogen bond falls in between a cap group nitrogen, and a gatekeeper residue Glu272 contributes to the tight binding. Unfortunately, however, the development of a high-selective HDAC10 inhibitor is still far off because of the inability to abrogate HDAC6 activity.

6.2 Design or synthesis of HDAC10 inhibitors

We also examined previous works on the design or synthesis of HDAC10 inhibitors. By changing the condition of building block reaction, Villadsen et al(151) synthesized azumamides A-E. In addition, they examined the inhibitory properties of HDAC10 under different drug concentrations (5μM and 50μM), which indicates both azumamides C and azumamides E markedly inhibit HDAC10. The HDACIs tubastatin A and PCI-34051 have the same N-benzylindole core(150, 152). After hybridizing these two inhibitors, Morgen et al(153) synthesized dihydroxamic acids, which significantly suppressed the viability of neuroblastoma cells and played the role of potent inhibitor of HDAC10. Uba et al.(137) constructed M0017, the best model of human HDAC10, and filtered out ZINC19749069, the highest-rank compound from the ZINC database, which displayed high stability when docking it into the catalytic channel of an HDAC10 model with quisinostat. Thus, M0017 and ZINC19749069 present considerable potential as an optimal HDACI and scaffold.

Although more and more studies could be reliably used for the HDACI designation, further exploration of the HDAC molecule structure and its biological characterization remain fundamental to shed light on the selection and development of the site-specific HDACIs.

7. Conclusion

Like other HDAC isoforms, HDAC10 exhibits various complex functions and clinic values(4, 154, 155). As mentioned above, its functions involve in DNA damage repair, gene transcription and autophagy, and HDAC10-mediated tumor cell proliferation, apoptosis, invasion, migration, angiogenesis, metastasis and immune regulation, laying the theoretical foundation for clinical application. However, there are still challenges to be met. First, more details on the mechanisms of aberrant HDAC10 regulatory are essential to provide a more
integrative understanding of HDAC10 and other HDACs. Besides, it has yet to be determined how to treat patients with HDAC1I resistance as well as the precise dose of HDAC1I. What is more, it remains unclear whether extending HDAC1I to other solid tumors would lead to satisfactory outcomes. With further in-depth study, HDAC10 may serve as an essential anti-tumor target and contribute to clinical applications in the future.

Acknowledgments
The authors gratefully thank the academic editor and the anonymous reviewers for their insightful comments and suggestions to improve this manuscript.

Author contributions
BZ, FJC drafted the manuscript. JWW, GTZ, ZSY, ZHN and WH revised the manuscript. All authors approved the final manuscript.

Conflict of Interest Statement
None declared.

Funding
None.

Data Availability Statement
This study includes no data deposited in external repositories.

ORCID
Wei He. https://orcid.org/0000-0002-4272-2891.

References
1. Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional
regulation. Annual review of biochemistry. 1998;67:545-79.

2. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41-5.

3. Berger SL. An embarrassment of niches: the many covalent modifications of histones in transcriptional regulation. Oncogene. 2001;20(24):3007-13.

4. Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, et al. HDAC8: a multifaceted target for therapeutic interventions. Trends in pharmacological sciences. 2015;36(7):481-92.

5. Tong JJ, Liu J, Bertos NR, Yang XJ. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic acids research. 2002;30(5):1114-23.

6. Hai Y, Shinsky SA, Porter NJ, Christianson DW. Histone deacetylase 10 structure and molecular function as a polyamine deacetylase. Nature communications. 2017;8:15368.

7. Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harbor perspectives in biology. 2014;6(4):a018713.

8. Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. BioEssays : news and reviews in molecular, cellular and developmental biology. 2005;27(4):408-15.

9. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Current opinion in cell biology. 2003;15(2):172-83.

10. Leipe DD, Landsman D. Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily. Nucleic acids research. 1997;25(18):3693-7.

11. Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Molecular cancer. 2020;19(1):5.

12. Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R, et al. Isolation and characterization of a novel class II histone deacetylase, HDAC10. The Journal of biological chemistry. 2002;277(8):6656-66.

13. Kao HY, Lee CH, Komarov A, Han CC, Evans RM. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. The Journal of biological chemistry. 2002;277(1):187-93.

14. Guardiola AR, Yao TP. Molecular cloning and characterization of a novel histone deacetylase HDAC10. The Journal of biological chemistry. 2002;277(5):3350-6.

15. Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(14):7835-40.

16. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 2000;408(6808):106-11.

17. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends in genetics : TIG. 2003;19(5):286-93.

18. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455-8.

19. Shinsky SA, Christianson DW. Polyamine Deacetylase Structure and Catalysis: Prokaryotic Acetylpolyamine Amidohydrolase and Eukaryotic HDAC10. Biochemistry. 2018;57(22):3105-14.

20. Kao HY, Downes M, Ordentlich P, Evans RM. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes & development. 2000;14(1):55-66.
21. Zhou X, Richon VM, Rifkind RA, Marks PA. Identification of a transcriptional repressor related to
the noncatalytic domain of histone deacetylases 4 and 5. Proceedings of the National Academy of
Sciences of the United States of America. 2000;97(3):1056-61.

22. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone
deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401(6749):188-93.

23. Wu R, Lu Z, Cao Z, Zhang Y. Zinc chelation with hydroxamate in histone deacetylases modulated
by water access to the linker binding channel. Journal of the American Chemical Society. 2011;133(16):6110-3.

24. Gantt SL, Joseph CG, Fierke CA. Activation and inhibition of histone deacetylase 8 by monovalent
cations. The Journal of biological chemistry. 2010;285(9):6036-43.

25. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein
Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795-800.

26. Avalos JL, Boeke JD, Wolberger C. Structural basis for the mechanism and regulation of Sir2
enzymes. Molecular cell. 2004;13(5):639-48.

27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.

28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.

29. Yang Y, Huang Y, Wang Z, Wang HT, Duan B, Ye D, et al. HDAC10 promotes lung cancer
proliferation via AKT phosphorylation. Oncotarget. 2016;7(37):59388-401.

30. Li Y, Zhang X, Zhu S, Dejene EA, Peng W, Sepulveda A, et al. HDAC10 Regulates Cancer Stem-
Like Cell Properties in KRAS-Driven Lung Adenocarcinoma. Cancer research. 2020;80(16):3265-78.

31. Fan W, Huang J, Xiao H. Histone deacetylase 10 suppresses proliferation and invasion by inhibiting
the phosphorylation of β-catenin and serves as an independent prognostic factor for human clear cell
renal cell carcinoma. International journal of clinical and experimental medicine. 2015;8(3):3734-42.

32. Revathidevi S, Munirajan AK. Akt in cancer: Mediator and more. Seminars in cancer biology. 2019;59:80-91.

33. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer cell. 2007;12(1):9-22.

34. Shan C, Lu Z, Li Z, Sheng H, Fan J, Qi Q, et al. 4-hydroxyphenylpyruvate dioxygenase promotes
lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-
AMPK/HDAC10/G6PD axis. Cell death & disease. 2019;10(7):525.

35. Jian G, Vosden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342-8.

36. Li Y, Peng L, Seto E. Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via
a Novel Let-7-HMGA2-Cyclin A2 Pathway. Molecular and cellular biology. 2015;35(20):3547-65.

37. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?
Trends in cell biology. 2003;13(2):65-70.

38. Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. Journal of
molecular medicine (Berlin, Germany). 2016;94(12):1313-26.

39. Sutherland RL, Musgrove EA. Cyclins and breast cancer. Journal of mammary gland biology and
neoplasia. 2004;9(1):95-104.

40. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. Journal of experimental & clinical
cancer research : CR. 2011;30(1):87.

41. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis.
Genes & development. 1999;13(15):1899-911.

42. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic
malignancies. Seminars in hematology. 1997;34(4 Suppl 5):9-19.

43. Gözte S, Coersmeyer M, Müller O, Sievers S. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells. International journal of oncology. 2014;45(4):1715-23.

44. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free radical biology & medicine. 2010;48(6):749-62.

45. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiological reviews. 2014;94(3):909-50.

46. Lee JH, Jeong EG, Choi MC, Kim SH, Park JH, Song SH, et al. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Molecules and cells. 2010;30(2):107-12.

47. Polacheck WJ, Zervantonakis IK, Kamm RD. Tumor cell migration in complex microenvironments. Cellular and molecular life sciences : CMLS. 2013;70(8):1335-56.

48. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nature reviews Cancer. 2018;18(9):533-48.

49. Saiki Y, Horii A. Multiple functions of S100A10, an important cancer promoter. Pathology international. 2019;69(11):629-36.

50. Castro-Castro A, Marchesin V, Monteiro P, Lodillinsky C, Rossé C, Chavrier P. Cellular and Molecular Mechanisms of MT1-MMP-Dependent Cancer Cell Invasion. Annual review of cell and developmental biology. 2016;32:555-76.

51. Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. Progress in molecular biology and translational science. 2017;147:1-73.

52. Zhao W, Han HB, Zhang ZQ. Suppression of lung cancer cell invasion and metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via histone acetylation. The international journal of biochemistry & cell biology. 2011;43(10):1459-68.

53. Song C, Zhu S, Wu C, Kang J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. The Journal of biological chemistry. 2013;288(39):28021-33.

54. Dong YW, Wang R, Cai QQ, Qi B, Wu W, Zhang YH, et al. Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells. Journal of hepatology. 2014;60(4):792-801.

55. SAVONS-H, Schmeel LC, Schmeel FC, Schmidt-Wolf IG. Targeting the Wnt/beta-catenin pathway in renal cell carcinoma. Anticancer research. 2014;34(8):4101-8.

56. Shang S, Hua F, Hu ZW. The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017;8(20):33972-89.

57. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature reviews Cancer. 2002;2(10):727-39.

58. Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. The international journal of biochemistry & cell biology. 2009;41(7):1441-51.

59. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. The journal of investigative dermatology Symposium proceedings. 2000;5(1):24-33.

60. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor...
beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer research. 1997;57(5):963-9.

61. Duan B, Ye D, Zhu S, Jia W, Lu C, Wang G, et al. HDAC10 promotes angiogenesis in endothelial cells through the PTPN22/ERK axis. Oncotarget. 2017;8(37):61338-49.

62. Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochemical and biophysical research communications. 2008;368(2):318-22.

63. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013;13(10):714-26.

64. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. The Journal of pathology. 2005;205(2):275-92.

65. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer. 2002;2(1):48-58.

66. Ridinger J, Koenke E, Kolbinger FR, Koerholz K, Mahboobi S, Hellweg L, et al. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. Scientific reports. 2018;8(1):10039.

67. Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, et al. Autophagy and multidrug resistance in cancer. Chinese journal of cancer. 2017;36(1):52.

68. Oehme I, Linke JP, Böck BC, Milde T, Lodrini M, Hartenstein B, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(28):E2592-601.

69. Oehme I, Lodrini M, Brady NR, Witt O. Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas. Autophagy. 2013;9(12):2163-5.

70. Islam MM, Banerjee T, Packard CZ, Kotian S, Selvendiran K, Cohn DE, et al. HDAC10 as a potential therapeutic target in ovarian cancer. Gynecologic oncology. 2017;144(3):613-20.

71. Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864-70.

72. Richard DJ, Savage K, Bolderson E, Cubeddu L, So S, Ghita M, et al. hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex. Nucleic acids research. 2011;39(5):1692-702.

73. Wu Y, Chen H, Lu J, Zhang M, Zhang R, Duan T, et al. Acetylation-dependent function of human single-stranded DNA binding protein 1. Nucleic acids research. 2015;43(16):7878-87.

74. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacology & therapeutics. 2013;140(3):223-38.

75. Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, et al. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(13):3149-62.

76. Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature medicine. 2017;23(9):1063-71.

77. Jin X, Yan Y, Wang D, Ding D, Ma T, Ye Z, et al. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Molecular cell. 2018;71(4):592-605.e4.
78. Sun H, Mediwal SN, Szafrran AT, Mancini MA, Marcelli M. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Hormones & cancer. 2016;7(3):196-210.

79. Saygin C, Matei D, Majeti R, Reizes O, Lathia JD. Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell stem cell. 2019;24(1):25-40.

80. Batlle E, Clevers H. Cancer stem cells revisited. Nature medicine. 2017;23(10):1124-34.

81. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012;148(5):1015-28.

82. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature. 2015;525(7568):256-60.

83. Dahiya S, Beier UH, Wang L, Han R, Jiao J, Akimova T, et al. HDAC10 deletion promotes Foxp3(+) T-regulatory cell function. Scientific reports. 2020;10(1):424.

84. Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. Journal of biomedical science. 2019;26(1):78.

85. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nature reviews Molecular cell biology. 2018;19(6):365-81.

86. Obayashi H, Nagano Y, Takahashi T, Seki T, Tanaka S, Sakai N, et al. Histone deacetylase 10 knockout activates chaperone-mediated autophagy and accelerates the decomposition of its substrate. Biochemical and biophysical research communications. 2020;523(1):246-52.

87. Arias E. Methods to Study Chaperone-Mediated Autophagy. Methods in enzymology. 2017;588:283-305.

88. Kaushik S, Cuervo AM. Methods to monitor chaperone-mediated autophagy. Methods in enzymology. 2009;452:297-324.

89. Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacology & therapeutics. 2018;189:45-62.

90. Li GM. Mechanisms and functions of DNA mismatch repair. Cell research. 2008;18(1):85-98.

91. Radhakrishnan R, Li Y, Xiang S, Yuan F, Yuan Z, Telles E, et al. Histone deacetylase 10 regulates DNA mismatch repair and may involve the deacetylation of MutS homolog 2. The Journal of biological chemistry. 2015;290(37):22795-804.

92. Tao X, Yan Y, Lu L, Chen B. HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma. Oncology letters. 2017;14(4):4923-9.

93. Park BL, Kim YJ, Cheong HS, Lee SO, Han CS, Yoon JH, et al. HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochemical and biophysical research communications. 2007;363(3):776-81.

94. Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes, chromosomes & cancer. 2012;51(10):949-60.

95. Uzdensky A, Demyanenko S, Bibov M, Sharifulin S, Kit O, Przhedetski Y, et al. Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(8):8225-33.

96. Kasaian K, Wiseman SM, Walker BA, Schein JE, Zhao Y, Hirst M, et al. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. BMC cancer. 2015;15:984.

97. Lourdusamy A, Rahman R, Grundy RG. Expression alterations define unique molecular
characteristics of spinal ependymomas. Oncotarget. 2015;6(23):19780-91.

98. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International journal of cancer. 2004;112(1):26-32.

99. Jin Z, Jiang W, Jiao F, Guo Z, Hu H, Wang L, et al. Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients. International journal of clinical and experimental pathology. 2014;7(9):5872-9.

100. Liu X, Wang Y, Zhang R, Jin T, Qu L, Jin Q, et al. HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC. Frontiers in oncology. 2020;10:485.

101. Van Damme M, Crompt E, Meuleman N, Mineur P, Bron D, Lagneaux L, et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics. 2012;7(12):1403-12.

102. Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C, et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology. 2011;81(5-6):325-9.

103. De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 1997;11(1):134-41.

104. De Rossi G, Zarcone D, Mauro F, Cerruti G, Tenca C, Puccetti A, et al. Adhesion molecule expression on B-cell chronic lymphocytic leukemia cells: malignant cell phenotypes define distinct disease subsets. Blood. 1993;81(10):2679-87.

105. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. Journal of cellular physiology. 2019;234(2):1313-25.

106. Kim JH, Moon SH, No M, Kim JJ, Choi EJ, Cho BJ, et al. Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization. Cancer research and treatment : official journal of Korean Cancer Association. 2016;48(3):1313-40.

107. Zhang HP, Wang L, Fu JJ, Fan T, Wang ZL, Wang G. Association between histone hyperacetylation status in memory T lymphocytes and allergen-induced eosinophilic airway inflammation. Respirology (Carlton, Vic). 2016;21(5):850-7.

108. Rocca L, Santonastasso M, Mottola F, Costagliola D, Suero T, Pacifico S, et al. Genotoxicity assessment of TiO2 nanoparticles in the teleost Danio rerio. Ecotoxicology and environmental safety. 2015;113:223-30.

109. Jayaram DT, Payne CK. Food-Grade TiO(2) Particles Generate Intracellular Superoxide and Alter Epigenetic Modifiers in Human Lung Cells. Chemical research in toxicology. 2020;33(11):2872-9.

110. Choi JS, Lee WJ, Baik SH, Yoon HK, Lee KH, Kim YH, et al. Array CGH reveals genomic aberrations in human emphysema. Lung. 2009;187(3):165-72.

111. Choi SY, Piao ZH, Jin L, Kim JH, Kim GR, Ryu Y, et al. Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling. PloS one. 2016;11(11):e0167340.

112. Guo Y, Gao W, Wang D, Liu W, Liu Z. Gene alterations in monocytes are pathogenic factors for immunoglobulin a nephropathy by bioinformatics analysis of microarray data. BMC nephrology. 2018;19(1):184.

113. Kebir O, Chaumette B, Fatjö-Vilas M, Ambalavanan A, Ramoz N, Xiong L, et al. Family-based association study of common variants, rare mutation study and epistatic interaction detection in HDAC genes in schizophrenia. Schizophrenia research. 2014;160(1-3):97-103.
114. Kim T, Park JK, Kim HJ, Chung JH, Kim JW. Association of histone deacetylase genes with schizophrenia in Korean population. Psychiatry research. 2010;178(2):266-9.

115. Wang L, Zheng S, Zhang L, Xiao H, Gan H, Chen H, et al. Histone Deacetylation 10 Alleviates Inflammation After Intracerebral Hemorrhage via the PTPN22/NLRP3 Pathway in Rats. Neuroscience. 2020;432:247-59.

116. González B, Bernardi A, Torres OV, Jayanthi S, Gomez N, Sosa MH, et al. HDAC superfamily promoters acetylation is differentially regulated by modafinil and methamphetamine in the mouse medial prefrontal cortex. Addiction biology. 2020;25(2):e12737.

117. Xin M, Yue T, Ma Z, Wu FF, Gow A, Lu QR. Myelination and axonal recognition by oligodendrocytes in brain are uncoupled in Olig1-null mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2005;25(6):1354-65.

118. Lu QR, Sun T, Zhu Z, Ma N, Garcia M, Stiles CD, et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell. 2002;109(1):75-86.

119. Dai J, Bercury KK, Jin W, Macklin WB. Olig1 Acetylation and Nuclear Export Mediate Oligodendrocyte Development. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2015;35(48):15875-93.

120. Srivastava A, Banerjee J, Dubey V, Tripathi M, Chandra PS, Sharma MC, et al. Role of Altered Expression, Activity and Sub-cellular Distribution of Various Histone Deacetylases (HDACs) in Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis. Cellular and molecular neurobiology. 2020.

121. Xu W, An X, Zhang N, Li L, Zhang X, Wang Y, et al. Middle-aged female rats lack changes in histone H3 acetylation in the anterior hypothalamus observed in young females on the day of a luteinizing hormone surge. Bioscience trends. 2019;13(4):334-41.

122. Lai IL, Lin TP, Yao YL, Lin CY, Hsieh MJ, Yang WM. Histone deacetylase 10 relieves repression on the melanogenic program by maintaining the deacetylation status of repressors. The Journal of biological chemistry. 2010;285(10):7187-96.

123. Qian H, Chen Y, Nian Z, Su L, Yu H, Chen FJ, et al. HDAC6-mediated acetylation of lipid droplet-binding protein CIDEC regulates fat-induced lipid storage. The Journal of clinical investigation. 2017;127(4):1353-69.

124. Funato H, Oda S, Yokofujita J, Igarashi H, Kuroda M. Fasting and high-fat diet alter histone deacetylase expression in the medial hypothalamus. PloS one. 2011;6(4):e18950.

125. Sonkar R, Powell CA, Choudhury M. Benzyl butyl phthalate induces epigenetic stress to enhance adipogenesis in mesenchymal stem cells. Molecular and cellular endocrinology. 2016;431:109-22.

126. Fanales-Belasio E, Raimondo M, Suligoi B, Buttó S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Annali dell'Istituto superiore di sanità. 2010;46(1):5-14.

127. Ran X, Ao Z, Trajtman A, Xu W, Kobinger G, Keynan Y, et al. HIV-1 envelope glycoprotein stimulates viral transcription and increases the infectivity of the progeny virus through the manipulation of cellular machinery. Scientific reports. 2017;7(1):1353-69.

128. Ran X, Ao Z, Oluikitibi T, Yao X. Characterization of the Role of Host Cellular Factor Histone Deacetylase 10 during HIV-1 Replication. Viruses. 2019;12(1).

129. Rodriguez M, Lapierre J, Ojha CR, Pawitwar S, Karuppan MKM, Kashanchi F, et al. Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes. Journal of neurovirology. 2019;25(2):263-74.
131. Pinto G, Shtaif B, Phillip M, Gat-Yablonski G. Growth attenuation is associated with histone deacetylase 10-induced autophagy in the liver. The Journal of nutritional biochemistry. 2016;27:171-80.

132. Liao W, Sun J, Liu W, Li W, Jia J, Ou F, et al. HDAC10 upregulation contributes to interleukin 1β-mediated inflammatory activation of synovium-derived mesenchymal stem cells in temporomandibular joint. Journal of cellular physiology. 2019;234(8):12646-62.

133. Luzzani C, Solari C, Losino N, Ariel W, Romorini L, Bluguermann C, et al. Modulation of chromatin modifying factors' gene expression in embryonic and induced pluripotent stem cells. Biochemical and biophysical research communications. 2011;410(4):816-22.

134. Schlüter A, Aksan B, Fioravanti R, Valente S, Mai A, Mauceri D. Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. Molecular neurobiology. 2019;56(12):8018-34.

135. Seo SM, Koh YS, Jung HO, Choi JS, Kim PJ, Baek SH, et al. Deoxyribonucleic Acid copy number aberrations in vasospastic angina patients using an array comparative genomic hybridization. Korean circulation journal. 2011;41(7):385-93.

136. Uba AI, Yelekçi K. Crystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10. Journal of biomolecular structure & dynamics. 2020;38(15):4397-406.

137. Ibrahim Uba A, Yelekçi K. Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors. Journal of biomolecular structure & dynamics. 2019;37(14):3627-36.

138. Thangapandian S, John S, Lee Y, Arulalapperumal V, Lee KW. Molecular modeling study on tunnel behavior in different histone deacetylase isoforms. PloS one. 2012;7(11):e49327.

139. Herbst-Gervasoni CJ, Christianson DW. Binding of N(8) -Acetylspermidine Analogues to Histone Deacetylase 10 Reveals Molecular Strategies for Blocking Polyamine Deacetylation. Biochemistry. 2019;58(49):4957-69.

140. Herbst-Gervasoni CJ, Steinbach RR, Morgen M, Miller AK, Christianson DW. Structural Basis for the Selective Inhibition of HDAC10, the Cytosolic Polyamine Deacetylase. ACS chemical biology. 2020;15(8):2154-63.

141. Codd R, Braich N, Liu J, Soe CZ, Pakchung AA. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. The international journal of biochemistry & cell biology. 2009;41(4):736-9.

142. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Molecular cancer therapeutics. 2006;5(7):1693-701.

143. Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P. HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget. 2017;8(47):83155-70.

144. De Souza C, Chatterji BP. HDAC Inhibitors as Novel Anti-Cancer Therapeutics. Recent patents on anti-cancer drug discovery. 2015;10(2):145-62.

145. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer research. 2004;64(3):1079-86.

146. Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S. Deacetylase inhibitors disrupt cellular
complexes containing protein phosphatases and deacetylases. The Journal of biological chemistry. 2004;279(9):7685-91.

148. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature biotechnology. 2011;29(3):255-65.

149. Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. European journal of medicinal chemistry. 2016;121:451-83.

150. Géraldy M, Morgen M, Sehr P, Steimbach RR, Moi D, Ridinger J, et al. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. Journal of medicinal chemistry. 2019;62(9):4426-43.

151. Villadsen JS, Stephansen HM, Maolanon AR, Harris P, Olsen CA. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²-epi-Azumamide E and β³-epi-Azumamide E. Journal of medicinal chemistry. 2013;56(16):6512-20.

152. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22(5):1026-34.

153. Morgen M, Steimbach RR, Géraldy M, Hellweg L, Sehr P, Ridinger J, et al. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. ChemMedChem. 2020;15(13):1163-74.

154. Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, et al. Histone deacetylase 6 in cancer. Journal of hematology & oncology. 2018;11(1):111.

155. Liu SS, Wu F, Jin YM, Chang WQ, Xu TM. HDAC11: a rising star in epigenetics. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020;131:110607.

Table and Figure Legends

Fig. 1. HDAC10 regulate cell proliferation, cell apoptosis, cell metastasis and angiogenesis in cancer cells.

- a. Roles of HDAC10 in cell proliferation.
- b. Roles of HDAC10 in cell apoptosis.
- c. Roles of HDAC10 in cell metastasis.
- d. Roles of HDAC10 in angiogenesis.

Fig. 2. Role of HDAC10 in non-tumor diseases and its clinical applications.
a. Role of HDAC10 in non-tumor diseases.

b. Clinical applications of HDAC10.

**Fig. 3.** Mechanisms of action of selective and non-selective HDAC10 inhibitors

**Table 1.** Overview of biological roles of HDAC10 in several malignant tumors.

| Role | Tumor Type |
|------|------------|
| NSCLC, non-small cell lung cancer. RCC, renal cell carcinoma. HCC, hepatic cell carcinoma. HBV, hepatitis B virus. AKT, protein kinase B. BCL2, B-cell lymphoma-2. TGF-β, transforming growth factor-β. AMPK, AMP-activated protein kinase. G6PD, glucose-6-phosphate dehydrogenase. ROS, reactive oxygen species. MMP-2, matrix metalloproteinase-2. MMP-9, matrix metalloproteinase-9. Hsp70, heat shock protein 70. VEGFR1, vascular endothelial growth factor receptor 1. VEGFR2, vascular endothelial growth factor receptor 2. LKB1, liver kinase B1. HMGA2, high mobility group A2. TCF7L2, transcription factor 7 like 2. SOX9, sex determining region Y box protein 9. NCOR2, nuclear receptor co-repressor 2. BRD4, bromodomain-containing protein 4. LAMP2A, lysosomal associated protein 2A. C/EBPα, CCAAT enhancer-binding proteins. hSSB1, human single-stranded DNA binding protein. flAR, full length androgen receptor. BRD4, bromodomain containing 4. BRD4, bromodomain containing 4. Cx43, connexin43. MLH1, mutL homolog 1. MSH2, mutS homolog 2. MSH6, mutS homolog 6. AR-V7, androgen receptor-V7. TXNIP, thioredoxin interacting protein. FSTL1, follistatin like 1. DUB3, ubiquitin specific peptidase 17 like family member 2. BAK, BCL2 antagonist/killer. Bid, BH3 interacting domain death agonist. LAMA4, laminin subunit alpha 4. MTSS1, MTSS I-BAR domain containing |

**Table 2.** Overview of selected biological roles of HDAC10 in non-tumor diseases.

| Role | Disease |
|------|---------|
| TiO₂, titanium dioxide. IgAN, immunoglobulin A nephropathy. ICH, intracerebral hemorrhage. MTLE-HS, mesial temporal lobe epilepsy with hippocampal sclerosis. LH, luteinizing hormone. HIV, human immunodeficiency virus. TMJ, temporomandibular joint. IL, interleukin. NF-κB, nuclear factor κB. mTOR, mammalian target of rapamycin. Hsp70, heat shock protein 70. IN, HIV-1 integrase. LEDGF, lens epithelium-derived growth factor. Pax3, paired box protein 3. KAP1, KRAB-associated protein 1. PTPN22, protein tyrosine phosphatase nonreceptor type 22. NLRP3, NOD-like receptors 3. | TiO₂, titanium dioxide. IgAN, immunoglobulin A nephropathy. ICH, intracerebral hemorrhage. MTLE-HS, mesial temporal lobe epilepsy with hippocampal sclerosis. LH, luteinizing hormone. HIV, human immunodeficiency virus. TMJ, temporomandibular joint. IL, interleukin. NF-κB, nuclear factor κB. mTOR, mammalian target of rapamycin. Hsp70, heat shock protein 70. IN, HIV-1 integrase. LEDGF, lens epithelium-derived growth factor. Pax3, paired box protein 3. KAP1, KRAB-associated protein 1. PTPN22, protein tyrosine phosphatase nonreceptor type 22. NLRP3, NOD-like receptors 3. |
| Tumor                        | Expression level | Function                      | Target/Signaling pathway                      | Cell line/Tissue                                                                 | Ref  |
|-----------------------------|------------------|-------------------------------|----------------------------------------------|----------------------------------------------------------------------------------|------|
| NSCLC                       | Elevated         | Cell proliferation, Cell apoptosis | AKT, BCL2, BAK                               | A549, H358 and H460 cell                                                         | 18   |
| Lung adenocarcinoma         | Elevated         | Cell proliferation, cancer stemness, Tumor immune | TGF-β pathway, SOX9, CD44, SLUG                | HDAC10 KO mice, HDAC10 WT mice                                                   | 19   |
| Lung cancer                 | Elevated         | Cell proliferation            | LKB1–AMPK signaling, G6PD, ROS                | H1299, H157, H1944, H460 and A549 cell                                          | 23   |
| Lung cancer                 | Elevated         | Cell proliferation, Cell cycle | H3, HMGA2                                     |                                                                                   | 25   |
| Lung cancer                 | Decreased        | Cell metastasis               | Cx43, FSTL1, H3, H4, S100A10, MMP-2, LAMA4, MTSS1 | PG cell                                                                         | 41   |
| RCC                         | Decreased        | Cell proliferation, cell invasion | β-catenin                                     | ACHN, Caki-2 cell, forty-five primary RCC tissues and adjacent normal tissues    | 20   |
| Gastric cancer              | /                | Cell apoptosis                | Caspase-3, Caspase-9, Bid, TXNIP, ROS         | SNU-620 cell                                                                     | 35   |
| Gastric cancer              | /                | Angiogenesis                  | Hsp70, VEGFR1, VEGFR2                        | SNU620 cell                                                                      | 51   |
| Colorectal cancer           | /                | Cell apoptosis                | Wnt pathway, TCF7L2                          | SW480, HCT116 cell                                                              | 32   |
| Colon cancer                | /                | Angiogenesis                  | Hsp70, VEGFR1, VEGFR2                        | HCT116 cell                                                                      | 51   |
| Colon cancer                | Elevated         | Mismatch repair               | MSH2, MLH1, MSH6                             | 100 colon cancer tissues                                                         | 81   |
| Cervical cancer             | /                | Cell metastasis               | MMP-2, MMP-9                                 | HeLa-S3 cell, 60 cancer tissue and normal tissue                                | 42   |
| Cervical cancer             | /                | Autophagy                     | LAMP2A-positive lysosome                      | HeLa cell                                                                        | 75   |
| Cervical cancer             | /                | Mismatch repair               | MSH2                                         | HeLa cell                                                                        | 80   |
| Cervical cancer and         | /                | Drug resistance               | hSSB1, p300                                   | HeLa and U2OS cells                                                              | 62   |
| Tissue Type               | Changes                                | Relevant Genes/Proteins                                                                 | Cell Line/ Sample Type                | References |
|--------------------------|----------------------------------------|---------------------------------------------------------------------------------------|--------------------------------------|------------|
| Osteosarcoma             | Cell metastasis                        | H3K9/14, C/EBPα, miR-223, integrin αV subunit                                        | SMMC-7721 cell                       | 43         |
| HCC                      | /                                      | Promoter polymorphism                                                                | 1095 HBV infection patient tissues   | 82         |
| Neuroblastoma            | Drug resistance                        | Lysosomal exocytosis, DNA damage                                                     | SK-N-BE(2)-C, IMR-32 and SK-N-AS cell| 55         |
| Neuroblastoma            | Drug resistance                        | Hsp70, Hsc70                                                                          | BE(2)-C, Kelly and IMR32 cell         | 57,58      |
| Ovarian                  | Decreased Drug resistance              | DNA repair                                                                            | UWB1.289 cell                        | 59         |
| Prostate cancer          | Drug resistance                        | AR-V7, flAR, BRD4, NCOR2, DUB3, BRD4                                                  | C4-2, PC-3, 22Rv1, DU145, LNCaP, VCaP and LAPC4 cells | 66,67      |
| Adrenocortical cancer    | Chromatin modulator                    | Methylation                                                                           | 44 adrenocortical cancer and 6 normal tissues | 83         |
| Melanoma                 | Decreased Gene expression              | Histone deacetylase                                                                   | melanoma tissue and normal samples   | 84         |
Table 2. Overview of selected biological roles of HDAC10 in non-tumor diseases.

| Disease                                   | Expression level | Functions                          | Targets/Signaling pathways          | Cell lines/ Tissues/ Animal model                        | Ref |
|-------------------------------------------|------------------|------------------------------------|------------------------------------|----------------------------------------------------------|-----|
| Eosinophilic airway inflammation          | Elevated         | Inhibit airway inflammation         | IL-4, IL-5, IL-13                  | CD4 + CD45RB<sup>low</sup> cell                          | 96  |
| TiO<sub>2</sub>-associated lung disease   | Elevated         | Cellular response                   | /                                  | A549 cell                                                | 97  |
| Emphysema                                 | /                | Pathogenic gene                     | Copy number gains                  | 32 emphysema blood samples                               | 99  |
| IgAN                                      | /                | Chromatin modifying enzymes         | /                                  | 8 IgAN blood samples and 9 normal blood samples          | 101 |
| Renal fibrosis                            | Elevated         | Regulate renal fibrosis             | /                                  | C57BL/6 male mice                                        | 100 |
| Schizophrenia                             | /                | Diagnostic value                    | /                                  | 278 Korean schizophrenia patients, 626 Caucasian        | 102 |
|                                            |                  |                                     |                                    | schizophrenia parents                                    |     |
|                                            |                  |                                     |                                    |                                                          | 103 |
| Post ICH inflammation                     | Decreased        | Aggravate inflammation response     | PTPN22/NLRP3                        | 6 ICH samples and S-D rat                                | 104 |
| Drug addiction                            | Elevated         | Affect cognitive function           | H4ac enrichment                    | C57BL/6 mice                                             | 105 |
| Multiple sclerosis                        | Decreased        | Affect oligodendrocytes             | oligo1 lysine 150 acetylation       | Mouse neural progenitor cells, HEK293T cell              | 108 |
| MTLE-HS                                   | Elevated         | Transcription regulation            | /                                  | 28 MTLE-HS samples                                       | 109 |
| LH secretion                              | Decreased        | Reduce LH secretion                 | H3 acetylation                      | S-D rat                                                  | 110 |
| Melanogenesis                             | /                | Promote melanogenesis               | Pax3/KAP1                           | HEK293 cell and B16F10 cell                              | 111 |
| Adipogenesis                              | Decreased        | Promote adipogenesis                | H3K9 acetylation                    | MSCs cell                                                | 114 |
| HIV infection                              | Decreased        | Promote HIV infection               | IN/LEDGF/p75, histone deacetylation | CD4<sup>+</sup> T-cell                                    | 116 |
| Nutrition-associated growth               | Elevated         | Inhibit cell viability              | mTOR, Hsp70, autophagy              | S-D rat, Huh7 cell                                       | 120 |
| TMJ inflammation                          | Decreased        | Inhibit inflammatory response        | IL-1β/NF-κB                         | 13 TMJ samples                                           | 121 |

Ref: Reference number for each study.
HDAC10

- TGF-β signaling pathway: Cancer cell stemness
- Foxp3+ Treg cell: Tumor immune and inflammation
- LAMP2A-positive lysosomes: Autophagy
- MSH2, MSH6, MLH1: Mismatch repair system
- Promoter polymorphism: Gene alteration
- Transcription regulation

Radio sensitization

- Selective HDACIs
- Pan-HDACIs
- HDACIs + other drugs

Target therapy

Clinical biomarker

Prognosis
Suppress cells proliferation

Induction of immune cells

Inhibit tumor growth

Regulate cytokines

Affect signaling pathways

Induce apoptosis

Inhibit Angiogenesis